Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the causal factors? Can it be avoided?

Natalizumab (Tysabri®) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, three patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with pro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Warnke, Clemens, Menge, Til, Hartung, Hans-Peter, Racke, Michael K., Cravens, Petra D., Bennett, Jeffrey L., Frohman, Elliot M., Greenberg, Benjamin M., Zamvil, Scott S., Gold, Ralf, Hemmer, Bernhard, Kieseier, Bernd C., Stüve, Olaf
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4157908/
https://ncbi.nlm.nih.gov/pubmed/20697042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2010.161
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars